Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small-molecule–in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Dobrovolsky, Dennis, Wang, Eric S., Morrow, Sara, Leahy, Catharine, Faust, Tyler, Nowak, Radosław P., Donovan, Katherine A., Yang, Guang, Li, Zhengnian, Fischer, Eric S., Treon, Steven P., Weinstock, David M., Gray, Nathanael S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6396177/
https://ncbi.nlm.nih.gov/pubmed/30545835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-862953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados